GENETIC ANALYSIS NK -60 (8V8) — Capital Reinvestment Ratio
GENETIC ANALYSIS NK -60 (8V8) has a Capital Reinvestment Ratio of 0.17x as of December 2025, meaning it reinvests 0% of its operating cash flow (€8.04 Million) in capital expenditures (€1.36 Million). Check GENETIC ANALYSIS NK -60 tangible book value ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
GENETIC ANALYSIS NK -60 Capital Reinvestment Ratio (2025–2025)
This chart tracks GENETIC ANALYSIS NK -60's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see 8V8 cash generation efficiency.
Annual Capital Reinvestment Ratio for GENETIC ANALYSIS NK -60 (2025–2025)
Year-by-year Capital Reinvestment Ratio for GENETIC ANALYSIS NK -60 from 2025 to 2025. See GENETIC ANALYSIS NK -60 free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 2.31x | €2.40 Million | €5.54 Million | — |